According to the World Health Organization a meager amount of antibiotics is undergoing development to fight the hazard of multi drug-resistant infections. The concern remains that it is plausible that the pace of intensifying struggle will surpass the slow going drug evolution procedure.

The new report said that the absolute of 51 antibiotics and 11 biological are being evolved. Peter Beyer, an author of the report and senior adviser to the WHO’s Department of Essential Medicines and Health Products, wrote in an email that biological could substitute use of antibiotics which will assist in conquering the resilience problem. Apparently the huge number of prospective new drugs should be sufficient yet it’s not enough.

There are 33 of the antibiotics in the pipeline focusing predominantly on pathogens. This year the WHO published a list of a dozen “priority pathogens”: 12 unrelated families of antibiotic-resistant bacteria that constitute considerable peril to human health.

Amidst the preeminent pathogens is drug-resistant tuberculosis which eliminates about 250000 people all over the world each year and an assortment of multi drug resistant strains – Acinetobacter, Pseudomonas and various Enterobacteriaceae – which are accountable for contamination in hospitals and nursing homes and also among patients who require ventilators and catheters.

Of the 33 possible medicines managing predominant bug infections, only 8 are unconventional treatments. The other 25 are straightforward mitigations of prevailing families of antibiotics. So the 25 will work as short term solutions since it is assumed bacteria will swiftly acclimatize to and withstand these new drugs according to WHO.